Results 31 to 40 of about 2,000 (98)

Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques

Papillomavirus Research, 2020
Human papillomavirus (HPV) causes not only most cervical cancers but also cancers of the vagina, vulva, penis, anus, rectum, and oropharynx. Every year, 200,000 women die of cervical cancer in the world, and China accounts for about 10%. HPV vaccines are
Yan Wang, Yuying Liu, Shutian Liang, Fei Yin, Haijiang Zhang, Yongjiang Liu   +5 more
doaj   +1 more source

Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. [PDF]

PLoS ONE, 2010
BACKGROUND: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™)
Holly J Corbett, Germain J P Fernando, Xianfeng Chen, Ian H Frazer, Mark A F Kendall   +4 more
doaj   +1 more source

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

Journal of Health Economics and Outcomes Research, 2022
# Background The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. # Objective To estimate and compare the health and economic outcomes of 2 HPV vaccination
Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels   +4 more
doaj   +2 more sources

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, Volume 136, Issue S4, Page S7-S17, September 2026.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

Ongoing challenges and future directions of human papillomavirus vaccination

Безопасность и риск фармакотерапии, 2020
Cervical cancer caused by human papillomavirus (HPV) types 16 and 18 is one of the most common cancer types in women. Other high-risk HPV types may cause vaginal cancer, vulval cancer, penile cancer, anal cancer, head and neck cancer. Low-risk HPV types,
O. S. Alyautdina, V. Yu. Prilutskaya
doaj   +1 more source

ATF4, ZIK1, and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies.
Angelo Borges de Melo Neto, Fábio Ribeiro Queiroz, Carolina Pereira de Souza Melo, Bruna Custódio Dias Duarte, Jorge Gomes Goulart Ferreira, Izabela Ferreira Gontijo de Amorim, Laurence Rodrigues do Amaral, Pedro Luiz Lima Bertarini, Telma Maria Rossi de Figueiredo Franco, Andréa Teixeira de Carvalho, Olindo Assis Martins‐Filho, Wander de Jesus Jeremias, Letícia da Conceição Braga, Paulo Guilherme de Oliveira Salles, Matheus de Souza Gomes   +14 more
wiley   +1 more source

Deep Mutational Scanning for the Study and Engineering of Protein Assemblies

Chemistry–Methods, Volume 6, Issue 8, August 2026.
This review explores how deep mutational scanning (DMS) can be used to improve understanding and accelerate engineering of protein assemblies, from natural fibers to engineered nanocages. We discuss various types of protein assemblies and their characterization, provide an introduction to the DMS technique, and then highlight examples in which DMS has ...
Jenna B. Wolfanger, Shoili Banerjee, Carolyn E. Mills   +2 more
wiley   +1 more source

Factors Associated With Cervical Cancer Awareness Among Women of Reproductive Age in the Democratic Republic of the Congo: Evidence From a Nationwide DHS Analysis

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Cervical cancer (CC) is a major public health concern, ranked as the fourth leading cause of cancer. Evidence shows that CC is preventable if detected and treated at the early stages. In the Democratic Republic of the Congo (DRC), national‐level evidence on women’s awareness of CC and its associated factors remains limited.
Jovinary Adam, Olivier Mukuku, Stanislas Maseb’a Mwang Sulu, Joseph Bulanda Nsambi, Janvier Mwemedi Tawi, Alphoncina Kagaigai, Pankras Luoga   +6 more
wiley   +1 more source

Influenza and Human Papillomavirus Vaccine Utilisation in Vulnerable Urban Youth in Edmonton, Alberta, Canada

The International Journal of Health Planning and Management, Volume 41, Issue 4, Page 572-579, July 2026.
ABSTRACT Introduction This project explores influenza and human papillomavirus (HPV) vaccine utilisation among a multi‐ethnic group of youth (aged 11–23 years) in Edmonton, Alberta, Canada. Method Using a cross‐sectional design and purposive sampling, influenza vaccine utilisation over 3 years was assessed via questionnaire.
Sarah Deck, Se Lim Jang, Rachel Harris, Fariba Kolahdooz, Moutasem Zakkar, Sangita Sharma   +5 more
wiley   +1 more source